Pancreatic Cancer News and Research

RSS

Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.

Antibodies boost immune system to fight childhood cancer, shows study

Researchers in the Antibody and Vaccine Group have developed two monoclonal antibodies (mAbs) called anti-4-1BB and anti-CD40 and investigated a third called anti-CTLA-4. Each of these antibodies binds to a different target molecule in the immune system, potentially heightening the body's own immune response to cancer.

12 Jul 2013

Protein that triggers blood clotting plays critical role in growth of pancreatic and breast cancer

A recently discovered form of the protein that triggers blood clotting plays a critical role in promoting the growth of metastatic pancreatic cancer and primary breast cancer, according to the cumulative findings from two new scientific manuscripts published online ahead of print in the International Journal of Cancer and PNAS (Proceedings of the National Academy of Sciences).

12 Jul 2013

Research shows mutations in FAM190A gene may contribute to chromosomal instability in cancer

Johns Hopkins cancer scientists have discovered that a little-described gene known as FAM190A plays a subtle but critical role in regulating the normal cell division process known as mitosis, and the scientists' research suggests that mutations in the gene may contribute to commonly found chromosomal instability in cancer.

4 Jul 2013

Scientists track down origins of fibrosis-promoting cells that scar and destroy organs

Scientists have tracked down and quantified the diverse origins of cells that drive fibrosis, the incurable, runaway wound-healing that scars and ultimately destroys organs such as the lungs, liver and kidneys.

2 Jul 2013

Case Comprehensive Cancer Center secures "outstanding" rating from NCI

The Case Comprehensive Cancer Center (CCCC) again demonstrated the compelling power of partnership in securing an overall rating of "outstanding" and a five-year renewal of its grant from the National Cancer Institute (NCI).

28 Jun 2013

Scientists make important step forward to find cure for cancer

Scientists at the University of East Anglia have made a major advancement in understanding tissue development that has important implications for cancer.

27 Jun 2013

TGen, Ventana sign research agreement to develop diagnostic markers for cancer

The Translational Genomics Research Institute and Ventana Medical Systems, Inc., a member of the Roche Group, today announced a collaborative research agreement to discover and develop diagnostic markers for treating cancer.

25 Jun 2013

Sorrento, IGDRASOL to present updates on IG-001 and IG-004 at joint meeting of CLINAM and ETPN

Sorrento Therapeutics, Inc. and IGDRASOL announced today that the companies will present updates of their analyses of proprietary late clinical stage paclitaxel formulations, IG-001 (Cynviloq) and IG-004 (TOCOSOL paclitaxel) at the joint meeting of the European Foundation for Clinical Nanomedicine and the European Technology Platform on Nanomedicine in Basel, Switzerland on June 23 - 26.

21 Jun 2013

Scientists use stem-cell technology to create research cell line from PDAC patient

Pancreatic cancer carries a dismal prognosis. According to the National Cancer Institute, the overall five-year relative survival for 2003-2009 was 6 percent.

21 Jun 2013

Eli Lilly, BIPI support ADA's call for independent review of incretin-based therapies

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company support the American Diabetes Association call for an independent review of the safety data of incretin-based therapies.

17 Jun 2013

Researchers are one step closer to treating type 1 diabetes

Researchers at Washington University School of Medicine in St. Louis have identified a way to trigger reproduction in the laboratory of clusters of human cells that make insulin, potentially removing a significant obstacle to transplanting the cells as a treatment for patients with type 1 diabetes.

14 Jun 2013

Nano-biosensors along with new imaging techniques can improve drug targeting in pancreatic cancer

UK and Australian scientists have been able to show ways in which we can markedly improve drug targeting of solid tumours, using tiny 'biosensors' along with new advanced imaging techniques.

12 Jun 2013

Drug regulators slow to pursue concerns about potential adverse effects of new diabetes drugs

The BMJ and Channel 4 Dispatches investigated and found that evidence suggesting potential harm from the drugs in industry studies has not been published.

10 Jun 2013

Precision Biologics reports findings from Phase I/IIA study of NPC-1C at ASCO meeting

Precision Biologics, in collaboration with investigators from Duke University, has been selected to present an abstract of findings from its Phase 2 clinical trial at the Annual Meeting of the American Society of Clinical Oncology.

4 Jun 2013

Personal values influence doctors' treatment recommendations

What treatment a doctor recommends for advanced cancer not only depends on medical aspects. His relationship to the individual patients and his own view of their life situation at their age play a role.

4 Jun 2013

Concerns raised about popular blood pressure, diabetes drugs

The Wall Street Journal reports that a senior FDA regulator is seeking stronger warnings about a class of blood pressure drugs that may be linked to higher cancer rates. Meanwhile, The New York Times details how a doctor hired by Merck to test a diabetes drug in rats found a possible link to pancreatic cancer, a discovery that turned the doctor into a crusader.

1 Jun 2013

First Edition: May 31, 2013

Today's early morning highlights from the major news organizations, including reports from the administration about the number of insurers that will be offering policies on the new online marketplaces.

31 May 2013

Sorrento Therapeutics, IGDRASOL announce publication of clinical data for Cynviloq and gemcitabine

Sorrento Therapeutics, Inc. and IGDRASOL announced today that clinical data for CynviloqTM, a non-biologic nanoparticle formulation of paclitaxel, plus gemcitabine was published for the upcoming Annual Meeting of the American Society of Clinical Oncology.

28 May 2013

Research shows PODXL protein contributes to aggressive forms of bladder cancer

Aggressive forms of bladder cancer involve the protein PODXL - a discovery that could hold the key to improved treatment, according to researchers at Lund University, Uppsala University and KTH in Sweden.

24 May 2013

FDA gives Priority Review to Celgene's ABRAXANE sNDA for advanced pancreatic cancer

Celgene International Sàrl, a subsidiary of Celgene Corporation today announced that the U.S. Food and Drug Administration has assigned a Priority Review designation to the supplemental New Drug Application for the use of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for the first-line treatment of patients with advanced pancreatic cancer.

23 May 2013